ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Novartis reports 'clinically relevant' survival data for Lutathera pharmatimes
June 04, 2021Novartis has reported findings of a final analysis of data from the Phase III Netter trial, showing that its radioligand therapy Lutathera (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) extended overall survival in patients ...
Pharma Sources Insight January 2025
